G1 Therapeutics, Inc.

GTHX

US3621LQ1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
4.53 ^USD	-3.21%		-5.03%	+48.52%

01/05	Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024
01/05	Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	MT

G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023

August 02, 2023 at 04:00 pm IST

G1 Therapeutics, Inc. provided Financial Guidance for the full year 2023. For the period, the company expects to generate between $50 million and $60 million in COSELA net revenue in 2023.

Latest news about G1 Therapeutics, Inc.

Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	01/05
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	01/05	MT
G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05	CI
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib	01/05	CI
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	28/02	MT
Transcript : G1 Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	28/02
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M	28/02	MT
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	28/02	CI
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Top Midday Decliners	14/02	MT
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	13/02	MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating	13/02	MT
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	13/02	MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating	13/02	MT
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study	13/02	MT
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	13/02	CI
Transcript : G1 Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	11/01
G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC	08/01	CI
Simcere Pharma Gets Authorization to Produce Imported Cancer Drug in Hainan Facility	28/12	MT
G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Biotechnology Index	15/12	CI
G1 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Transcript : G1 Therapeutics, Inc., Q3 2023 Earnings Call, Nov 01, 2023	01/11
Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q3 Revenue $12.3M, vs. Street Est of $14.2M	01/11	MT
G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023	01/11	CI

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Sector

Biotechnology & Medical Research

Calendar

31/05/2024 - American Society of Clinical Oncology Annual Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for G1 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.68 USD

Average target price

8.5 USD

Spread / Average Target

+81.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
G1 THERAPEUTICS, INC.	+48.52%	245M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs